Latest filing published 13 Jan 2026 for LISATA THERAPEUTICS, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Mohammad Azab across 3 companies, led by Lisata Therapeutics, Inc., Durect Corp and Xenon Pharmaceuticals Inc. Over a trading history stretching from 15 December 2021 to 9 January 2026, the count stands at 11 filings.
On the market, this insider has only ever bought: 2 purchases, €5,436 in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 5 share grants and 3 option exercises.
Most recently, on 13 January 2026, the filings show a share grant in Lisata Therapeutics, Inc. The latest purchase dates back some time: it was published 1,607 days ago, on 25 May 2022. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations